Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 5/20 | 0.67 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.63 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.63 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8323443 | 1.00 | GRM5 (0.67) | GRM5PARP10PARP11RYR2PARP1 | |
| SCHEMBL3692167 | 0.90 | GRM5 (0.56) | GRM5PARP10PARP11RYR2PARP1 | |
| SCHEMBL8161680 | 0.88 | PARP11 (0.68) | GRM5PARP10PARP11PARP1PDPK1 | |
| SCHEMBL29438649 | 0.87 | PARP10 (0.63) | GRM5PARP10PARP11RYR2PARP1 | |
| SCHEMBL246378 | 0.87 | PARP10 (0.63) | GRM5PARP10PARP11RYR2PARP1 | |
| SCHEMBL12230826 | 0.86 | PARP10 (0.56) | GRM5PARP10PARP11RYR2PARP1 | |
| SCHEMBL8154135 | 0.84 | PARP10 (0.69) | GRM5PARP10PARP11PARP1PDPK1 | |
| SCHEMBL504342 | 0.84 | GRM5 (0.79) | GRM5PARP10PARP11MAPKAPK2 | |
| SCHEMBL12077584 | 0.84 | RYR2 (0.51) | GRM5PARP10PARP11RYR2KDM4E | |
| SCHEMBL21040262 | 0.83 | PARP11 (0.55) | GRM5PARP10PARP11PARP1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617811-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | GLENMARK SPECIALITY S.A. (CH) | 2026-03-17 | — | — | US | disclosed |
| CN-121449553-A | Synthesis method of 6- (methoxy) -3, 4-dihydro-1 (2H) -isoquinolone | 凯美克(上海)医药科技有限公司 | 2026-02-03 | — | — | CN | disclosed |
| CN-121449553-A | Synthesis method of 6- (methoxy) -3, 4-dihydro-1 (2H) -isoquinolone | 凯美克(上海)医药科技有限公司 | 2026-02-03 | — | — | CN | disclosed |
| EP-4678644-A1 | SUBSTITUTED DIHYDROTHIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Yidi Biotechnology Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| CN-114621207-B | Compound serving as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-114555585-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-114195764-B | Compound serving as thyroid hormone beta receptor agonist and application thereof | 广东东阳光药业股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| CN-116096370-B | HPK1 inhibitors and uses thereof | 锐格药业公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-0526402-B1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA GEIGY AG (CH) | 1998-01-21 | — | — | EP | disclosed |
| US-5707994-A | USEFUL AS A PLATELET AGGREGATION INHIBITOR, CANCER METASTASIS INHIBITOR, WOUND HEALING AGENT OR A BONE RESORPTION INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-01-13 | — | — | US | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| CN-1138322-A | 2,3-diaminopropionic acid derivative | SUMITOMO PHARMA (JP) | 1996-12-18 | — | — | CN | disclosed |
| EP-0725059-A1 | 2,3-DIAMINOPROPIONIC ACID DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-08-07 | — | — | EP | disclosed |
| US-5350761-A | Lipoxygenase inhibitors as antiinflammatory agents and antiallergens | CIBA-GEIGY CORPORATION (US) | 1994-09-27 | — | — | US | disclosed |
| US-5334600-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1994-08-02 | — | — | US | disclosed |
| US-5260316-A | Lipoxygenase inhibitor | CIBA-GEIGY CORPORATION (US) | 1993-11-09 | — | — | US | disclosed |
| EP-0526402-A1 | Heteroaryl substituted hydroxylamine derivatives as lipoxygenase inhibitors | CIBA-GEIGY AG (CH) | 1993-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | GRM5 2942/4885PARP10 810/4885PARP11 604/4885 |
| US-12617811-B2 | HPK1 inhibitors and uses thereof | MAP2K4, MAP2K1, MAP2K3 | GRM5 4700/4885PARP10 1083/4885PARP11 1218/4885 |
| US-12577267-B2 | Pyrimidine compounds for use as MAP4K1 inhibitors | PTK2B, MAP3K10, MAP3K20 | GRM5 4066/4885PARP10 700/4885PARP11 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.